- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01413711
An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms
September 12, 2012 updated by: Lundbeck LLC
The primary objective of the study is to evaluate vigabatrin pharmacokinetics (PK) in neonates receiving vigabatrin for infantile spasms (IS); and to determine the safety of vigabatrin.
Study Overview
Study Type
Interventional
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 month to 6 months (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The patient's parent or legally authorized representative is able to read and understand the Patient Information Sheet and Informed Consent Form.
- The patient's legally authorized representative has signed the Informed Consent Form.
- The patient has IS, diagnosed according to the International League Against Epilepsy (ILAE) criteria.
- The patient is a full term (38 weeks gestation) male or female, aged >=1 month to <6 months at the time of enrollment.
- The patient's length and body weight for gestational age is >=5th and <=95th percentile, according to Centers for Disease Control and Prevention (CDC) Growth Charts.
Exclusion Criteria:
- The patient is currently being treated or has been previously treated with vigabatrin.
- The patient is a member of the site personnel's immediate family.
- The patient takes or has taken disallowed recent or concomitant medication or it is anticipated that the patient will require treatment with at least one of the disallowed concomitant medications during the study.
- The patient has a history of severe drug allergy or hypersensitivity, or known hypersensitivity to the investigational medicinal product (IMP) or the excipients (povodone/iodine) of the IMP.
- The patient has any other disorder for which the treatment takes priority over treatment of IS or is likely to interfere with study treatment or impair treatment compliance.
- The patient has been treated with any IMP within 30 days or 5 half lives (whichever is longer) prior to the Screening Visit.
- The patient has a disease or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study.
- The patient has been diagnosed or is judged by the investigator to have anemia.
- The patient has been diagnosed or is judged by the investigator to have renal insufficiency.
- The patient's parent or legally authorized representative is, in the investigator's opinion, unlikely or unwilling to comply with the protocol or the patient is unsuitable for any reason.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vigabatrin
|
Oral vigabatrin as a single 25 mg/kg dose on Days 1 and 5, 25 mg/kg twice a day (50 mg/kg daily dose, orally) on Days 2-4
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Non-compartmental pharmacokinetic profile of vigabatrin after oral administrations in infants(>=1 and <6 months of age)
Time Frame: 24 hrs post dose on Day 1 and 12 hrs post dose on Day 5
|
Serial blood for plasma generation will be collected on Days 1 and 5 and vigabatrin concenrations determined to the determine the pharmacokinetic profile of vigabatrin
|
24 hrs post dose on Day 1 and 12 hrs post dose on Day 5
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the safety of vigabatrin following oral dose administrations in infants (>=1 and <6 months of age)
Time Frame: Safety collected throughout the 5-day study
|
Safety and tolerability parameters such as adverse events, clinical safety laboratory tests and vital signs will be summarised using descriptive statistics
|
Safety collected throughout the 5-day study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2012
Primary Completion (Anticipated)
September 1, 2013
Study Registration Dates
First Submitted
June 17, 2011
First Submitted That Met QC Criteria
August 9, 2011
First Posted (Estimate)
August 10, 2011
Study Record Updates
Last Update Posted (Estimate)
September 13, 2012
Last Update Submitted That Met QC Criteria
September 12, 2012
Last Verified
September 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Epilepsy, Generalized
- Epileptic Syndromes
- Neurologic Manifestations
- Neuromuscular Manifestations
- Epilepsy
- Spasms, Infantile
- Spasm
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- GABA Agents
- Anticonvulsants
- Vigabatrin
Other Study ID Numbers
- 13453A
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infantile Spasms
-
University of Colorado, DenverMallinckrodtRecruitingInfantile Spasms, Non-IntractableUnited States
-
Assistance Publique - Hôpitaux de ParisOSO-AIRecruiting
-
Bio-Pharm Solutions Co., Ltd.TerminatedRefractory Infantile SpasmsUnited States, Korea, Republic of
-
UCB Biopharma S.P.R.L.TerminatedInfantile Spasms (IS)France
-
Radius Pharmaceuticals, Inc.TerminatedInfantile SpasmUnited States
-
Children's Hospital of Orange CountyRecruiting
-
CerecinActive, not recruiting
-
University of Colorado, DenverPediatric Epilepsy Research Foundation; West Therapuetics, IncSuspended
-
Suvasini SharmaUnknownInfantile SpasmIndia
-
Jazz PharmaceuticalsCompletedInfantile SpasmsUnited States, Poland
Clinical Trials on Vigabatrin
-
Barbara J. CoffeyCompletedTourette's DisorderUnited States
-
Orphelia PharmaHospices Civils de Lyon; Institut National de la Santé Et de la Recherche Médicale... and other collaboratorsCompleted
-
University of PennsylvaniaH. Lundbeck A/STerminatedComplex Partial SeizuresUnited States
-
University of FloridaYale University; American Heart Association; Thomas Jefferson UniversityCompletedComa | Status Epilepticus, ElectrographicUnited States
-
University of ArizonaArizona Department of Health ServicesUnknownHypertension | Insulin Resistance | Hyperinsulinism | Glucose Intolerance | Insulin Sensitivity
-
Seoul National University HospitalWithdrawnAutoimmune EncephalopathyKorea, Republic of
-
Orphelia PharmaCompletedTherapeutic EquivalencyFrance
-
Baylor College of MedicineUniversity of California, Los AngelesCompletedMethamphetamine AddictionUnited States
-
Catalyst Pharmaceuticals, Inc.Completed
-
AmzellWithdrawnSpasms, InfantileItaly, Argentina, France, United States, Spain, India, Poland, Mexico